Efficacy of antiviral therapy and host-virus interactions visualised using serial liver sampling with fine-needle aspirates

Novel therapies for chronic hepatitis B (CHB), such as RNA interference, target all viral RNAs for degradation, whereas nucleoside analogues are thought to block reverse transcription with minimal impact on viral transcripts. However, limitations in technology and sampling frequency have been obstac...

Full description

Saved in:
Bibliographic Details
Main Authors: Kim, Samuel (Author) , Wallin, Jeffrey J. (Author) , Ghosheh, Yanal (Author) , Zahoor, Muhammad Atif (Author) , Sanchez Vasquez, Juan Diego (Author) , Nkongolo, Shirin (Author) , Fung, Scott (Author) , Mendez, Patricia (Author) , Feld, Jordan J. (Author) , Janssen, Harry L. A. (Author) , Gehring, Adam J. (Author)
Format: Article (Journal)
Language:English
Published: September 2023
In: JHEP reports
Year: 2023, Volume: 5, Issue: 9, Pages: 1-10
ISSN:2589-5559
DOI:10.1016/j.jhepr.2023.100817
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.jhepr.2023.100817
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S2589555923001489
Get full text
Author Notes:Samuel C. Kim, Jeffrey J. Wallin, Yanal Ghosheh, Muhammad Atif Zahoor, Juan Diego Sanchez Vasquez, Shirin Nkongolo, Scott Fung, Patricia Mendez, Jordan J. Feld, Harry L.A. Janssen, Adam J. Gehring
Description
Summary:Novel therapies for chronic hepatitis B (CHB), such as RNA interference, target all viral RNAs for degradation, whereas nucleoside analogues are thought to block reverse transcription with minimal impact on viral transcripts. However, limitations in technology and sampling frequency have been obstacles to measuring actual changes in HBV transcription in the liver of patients starting therapy.
Item Description:Online veröffentlicht am 19. Juni 2023, Artikelversion vom 4. August 2023
Gesehen am 07.12.2023
Physical Description:Online Resource
ISSN:2589-5559
DOI:10.1016/j.jhepr.2023.100817